Press release
Paris, September 22, 2026

Orange strengthens its life sciences innovation ecosystem with investment in French health-tech start-up Biolevate

- **Investment by Orange Ventures reinforces Orange's commitment to French Tech and trusted innovation in healthcare**
- **Orange Business combines Biolevate's knowledge-driven automation and trusted AI agents with Enovalife's clinical research, data and AI, and integration expertise to support Life Sciences customers**

Orange today announced that Orange Ventures has invested in Biolevate, a French health-tech start-up specializing in knowledge-driven automation to accelerate the path to market for drugs and other life sciences products. This investment, made as part of Biolevate's latest financing round, reflects Orange's commitment to support the French Tech ecosystem, helping high potential companies scale in strategic sectors. It also illustrates Orange's ambition, under its Trust the future strategy, to foster trusted digital solutions that combine innovation, security, responsible AI and operational value for business, especially in the healthcare and life sciences sectors.

Through Orange Ventures, Orange supports high-growth companies that can create technological, commercial, and strategic synergies with the Group, notably in data and AI, digital enterprise and e-health.

Biolevate is part of the 2025 French Tech 2030 promotion, whose companies develop technologies considered strategic for French technological sovereignty. The company has also been supported by Future4Care, the leading European ecosystem for AI in healthcare, of which Orange is a cofounder.

Supporting the transition from AI experimentation to operational adoption

Biolevate is already creating impact, with up to 50% faster time-to-market for selected pharmaceutical processes, dramatically reducing the time between the discovery of a potentially life-saving treatment and patient access. Its agentic AI platform captures, structures and operationalizes validated scientific and regulatory knowledge, enabling trusted AI agents to support complex work across the healthcare innovation lifecycle, from drug R&D and clinical operations to market access, health technology assessments, literature reviews and regulatory activities.

Alongside Orange Ventures' investment, Orange Business will work with Biolevate to combine its agentic AI capabilities with Enovalife's clinical research and data and AI transformation expertise. An Orange Business affiliate, Enovalife helps pharmaceutical customers streamline the drug lifecycle and address operational costs and regulatory demands through data and AI transformation. Its deep, long-standing relationships with research teams, and its understanding of their processes, operational constraints and transformation priorities, will help the partners support customers in developing and integrating agentic AI transformation projects more easily and effectively.

As pharmaceutical companies move beyond proofs of concept, the priority is to scale AI initiatives rapidly and sustainably, while maintaining control over maintenance costs. Together, Biolevate and Enovalife will focus on high-value clinical-development use cases where digital transformation and operational integration are essential for successful adoption. These include automating clinical trial protocol development, clinical study reports, and regulatory bridging, where documentation and compliance requirements must be adapted across jurisdictions.

Joel Belafa, CEO of Biolevate, said: "Our mission is to reduce the time between a potentially life-saving discovery and the moment it reaches patients. We do this through knowledge-driven automation for life sciences, paving the way for faster therapies through trusted AI agents. Orange Ventures' investment in our second financing round, together with our strategic partnership with Orange Business, Enovalife and Future4Care, creates a strong opportunity to scale this impact for life sciences organizations in France, Europe and globally."

Claire Scotton, Vice President, Healthcare and Life Sciences, Orange Business, said: "The priority for pharmaceutical R&D organizations is no longer simply to test AI, but to deploy it at scale in ways that create value for teams and fit their operations. Biolevate brings a highly relevant approach to knowledge-driven automation for life sciences and trusted AI agents. Enovalife contributes deep sector knowledge and proven integration capabilities. Together we aim to help customers accelerate their AI transformation, improve the consistency of clinical and regulatory processes, and keep human expertise at the heart of innovation."

About Orange Business

Orange Business, the enterprise division of the Orange Group, is a leading network and digital integrator, supporting customers to create positive impact and digital business. The combined strength of its next-generation connectivity, cloud, and cybersecurity expertise, platforms, and partners provides the foundation for enterprises around the world. With 30,000 employees across 65 countries, Orange Business enables its customers' transformations by orchestrating end-to-end secured digital infrastructure and focusing on the employee, customer, and operational experience. More than 30,000 B-to-B customers put their trust in Orange Business globally.

Orange is one of the world's leading telecommunications operators. As of the end of 2025, Orange connects 340 million customers (including MasOrange) across 26 countries and generated 40.4 billion euros in revenues.
Orange is listed on the Euronext Paris (ORA). For more information: www.orange-business.com or follow us on LinkedIn and on X: @orangebusiness

About Biolevate

Biolevate builds evidence-grade AI for regulated life sciences operations. The platform combines scientific evidence, regulatory knowledge, company context, governed workflows, and AI agents to help teams automate complex work while preserving traceability, auditability, reproducibility, and human control. Biolevate enables life sciences organisations to move beyond isolated AI tools and build knowledge-driven automations that can safely support regulated work at scale.

Press contacts:
Elizabeth Mayeri, Orange Business, elizabeth.mayeri@orange.com
Emmanuel Nahmany, Orange Business, emmanuelle.nahmany@orange.com
Biolevate PR Team, biolevate@kekstcnc.com